Victoria Alice JENKINS

Dr. Victoria Alice JENKINS

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2020 in Expert Review of Vaccines
Verified
Journal Article
Open access
WKWalid Kandeil
Walid Kandeil
CECaroline van Den Ende
Caroline van Den Ende
EBEveline M. Bunge
Eveline M. Bunge
VJVictoria Alice JENKINS
Victoria Alice JENKINS
MCMaria Angeles Ceregido
Maria Angeles Ceregido
AGAdrienne Guignard
Adrienne Guignard
Infants too young to be fully immunized are the most vulnerable to severe pertussis disease. To close this susceptibility gap, passive infant immunization through vaccination of pregnant women agai...

30 March 2025 in The Lancet
Verified
Journal Article
Closed access
JRJason S Richardson
Jason S Richardson
Deborah AndersonDeborah Anderson
Deborah Anderson
JMJason Mendy
Jason Mendy
LTLauren C Tindale
Lauren C Tindale
SMSufia Muhammad
Sufia Muhammad
LBLisa Bedell
Lisa Bedell

16 April 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
VJVictoria Alice JENKINS
Victoria Alice JENKINS
MSMiloje Savic
Miloje Savic
WKWalid Kandeil
Walid Kandeil
Infectious diseases can impact chronic medical conditions. However, it is currently not clear how pertussis correlates with preexisting or underlying disorders. We reviewed literature from the last 25 years to describe the burden and impact of pertussis infection in specific risk groups in individuals aged ≥11 years. Our literature search returned 543 hits, of which 18 were eligible for this review. Adolescents and adults with underlying conditions, such as asthma, chronic obstructive pulmonary disease (COPD), or obesity are potentially at increased risk of pertussis infection. Immunodeficiency and smoking have also been associated with worsened pertussis symptoms and an increased pertussis-related hospitalization rate. In patients with pertussis and preexisting asthma or COPD, symptoms were worsened, and health-care costs were consequently increased. Further efforts are needed to close the knowledge gap and to understand the burden of pertussis in at-risk adolescent and adult populations to help inform vaccination strategies and recommendations.

23 May 2022 in Ticks and Tick-borne Diseases
Verified
Journal Article
Open access
VJVictoria Alice JENKINS
Victoria Alice JENKINS
GSGuenter Silbernagl
Guenter Silbernagl
LBLorraine R. Baer
Lorraine R. Baer
BHBernard Hoet
Bernard Hoet
Health control measures instituted in 2020 to mitigate the COVID-19 pandemic decreased the case numbers of many infectious diseases across Europe. One notable exception was tick-borne encephalitis (TBE). In Austria, Germany, Switzerland, Lithuania, and the Czech Republic, the upturn was significantly higher compared to the average of the three years previously (P<0.05), with increases of 88%, 48%, 51%, 28%, and 18%, respectively. Six countries reported TBE incidences of ≥5 cases/100,000, defined as highly endemic by the World Health Organization (WHO). Possible factors contributing to this surge may include increased participation in outdoor activities in endemic regions and increased tick counts/tick activity. In highly endemic regions, the WHO recommends that vaccination be offered to all age groups, including children.

7 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
VJVictoria Alice JENKINS
Victoria Alice JENKINS
BHBernard Hoet
Bernard Hoet
HHHubertus Hochrein
Hubertus Hochrein
LMLaurence De Moerlooze
Laurence De Moerlooze
Respiratory syncytial virus (RSV) is a common cause of paediatric respiratory tract infection and causes a significant health burden in older adults. Natural immunity to RSV is incomplete, permitting recurrent symptomatic infection over an individual’s lifespan. When combined with immunosenescence, this increases older adults’ susceptibility to more severe disease symptoms. As RSV prophylaxis is currently limited to infants, older adults represent an important target population for RSV vaccine development. The relationship between RSV and our immune systems is complex, and these interactions require deeper understanding to tailor an effective vaccine candidate towards older adults. To date, vaccine candidates targeting RSV antigens, including pre-F, F, G (A), G (B), M2-1, and N, have shown efficacy against RSV infection in older adults in clinical trial settings. Although vaccine candidates have demonstrated robust neutralising IgG and cellular responses, it is important that research continues to investigate the RSV immune response in order to further understand how the choice of antigenic target site may impact vaccine effectiveness. In this article, we discuss the Phase 3 vaccine candidates being tested in older adults and review the hurdles that must be overcome to achieve effective protection against RSV.

22 July 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
JBJulianne Bayliss
Julianne Bayliss
RRRoshnee Randhawa
Roshnee Randhawa
KOKyu-Bin Oh
Kyu-Bin Oh
WKWalid Kandeil
Walid Kandeil
VJVictoria Alice JENKINS
Victoria Alice JENKINS
MNMichael Nissen
Michael Nissen
Adult vaccination in Australia is suboptimal. For instance, as few as one in nine people have received a pertussis vaccine in adolescence or adulthood, despite increasing disease burden and evidence of a positive correlation between older age and hospitalization rates. The objectives of this study were to describe general practitioners’ (GPs) and adult consumers’ knowledge and attitudes toward adult vaccination, with an emphasis on pertussis. Australian GPs and consumers were recruited in two nationally representative online surveys repeated annually between 2014 and 2018. Vaccination discussions occurred in a minority of adult/GP encounters. Pertussis was among the five most frequently identified vaccine preventable diseases but was unlikely to be proactively discussed with adults not in contact with young children. Among consumers, only one in three recalled ever receiving a pertussis vaccination. GPs are a strong predictor of adults receiving a pertussis vaccine. Possible factors contributing to low uptake are misconceptions around pertussis disease, vaccination requirements and lack of GP recommendation for adult vaccination. GPs have a key role to play in increasing adult vaccination coverage with their recommendation.